search
Back to results

Temple Touch Pro (TTP) Non-Invasive Core Temperature Monitoring as a Measure for Early Detection of Fever Related Infections, Including Sepsis. (TTP)

Primary Purpose

Patients in ICU

Status
Unknown status
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
TTP
Sponsored by
Medisim Ltd
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Patients in ICU

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Study Participants - Patients hospitalized in ICU department.

Inclusion Criteria:

The Retrospective Phase

  • Both genders (Male or Female).
  • Aged 18 years and/or above.
  • Patients were Admitted to our ICU for more than 3 days, and shall be at least 72 hours prior to sepsis or infection detection in the ICU The Prospective Phase

    • Both genders (Male or Female).
    • Aged 18 years and/or above. Patients expected to be admitted to our ICU for more than 3 days

Exclusion Criteria:

The patients will be excluded from the trial if one of the following occurs:

The Retrospective Phase

  • No exclusion criteria The Prospective Phase

    - The medical staff decides that the patien t should not participate.

  • Unavailable measurement site in case of head injury in the head area.
  • Unavailable measurement reading during admission to ICU

Sites / Locations

  • Hadassah Medical Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

patients in ICU

Arm Description

Outcomes

Primary Outcome Measures

Continuously measure body temperature using TTP
During the trial, temperature measurements will be conducted using the TTP™ and currently used thermometers which are in routine use, later to be regarded as reference methods To examine the effectiveness of the TTP™ as a measure for detection of temperature changes pattern and to correlate such changes with fever related to infections such as sepsis.

Secondary Outcome Measures

Full Information

First Posted
June 12, 2017
Last Updated
June 19, 2017
Sponsor
Medisim Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT03195439
Brief Title
Temple Touch Pro (TTP) Non-Invasive Core Temperature Monitoring as a Measure for Early Detection of Fever Related Infections, Including Sepsis.
Acronym
TTP
Official Title
Temple Touch Pro (TTP) Non-Invasive Core Temperature Monitoring as a Measure for Early Detection of Fever Related Infections, Including Sepsis.
Study Type
Interventional

2. Study Status

Record Verification Date
June 2017
Overall Recruitment Status
Unknown status
Study Start Date
October 2017 (Anticipated)
Primary Completion Date
April 2019 (Anticipated)
Study Completion Date
October 2019 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medisim Ltd

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No

5. Study Description

Brief Summary
The study has 2 phases: The Retrospective Phase (50 patients were diagnosed to have sepsis according to our definition and criteria and 30 patients as a controlled cases ) The Prospective Phase (600 patients who will be admitted and monitored in ICU in order to get at least 30 sepsis cases, according to our definition and criteria). Measurements will be made from the forehead using the TTP's biocompatible sensor Unit that will be attached to the skin. The SU will transfer data to the MCU.
Detailed Description
TTP™ system, which is composed of 2 parts: SU - a disposable Sensor Unit patch MCU - e reusable Monitor Connecting Unit The communication between the two units can be wired or wireless. The system to be used in this study is wired and the two units were connected via a Sensor Unit Cable (SCU). The SU is attached to the temple area by a biocompatible disposable adhesive. It measures skin temperature across the temporal artery using several sensors, translates it to electrical signals and transmits those signals to the MCU. The MCU translates the electrical signals to core temperature using a special mathematical algorithm which overcomes the effect of the ambient temperature as well as the thermal properties of a specific patient. The core temperature as well as any concurrent error in the measurement process is displayed on the screen of the MCU or transmitted to the hospital VSM. The MCU has a wired connection to the hospital's VSM using Standard YSI400. Study Objectives The objectives of this clinical study are: A first objective of the clinical study is to verify the findings of a previously published study, relating to temperature pattern changes within patients who were diagnosed having sepsis , prior to its occurrence. A second objective is to examine the efficacy and safety of the TTP - a novel non-invasive core temperature measurement system , as a measure for continues core temperature monitoring. A third objective of the study, is to examine the effectiveness of the TTP as a measure for detection of temperature changes pattern and to correlate such changes with fever related to infections such as sepsis. It is estimated that the study with take 18 months to complete. Type of Study A Retrospective phase. A prospective phase Temperature measurements Measurements will be made from the forehead using the TTP's biocompatible sensor Unit that will be attached to the skin The SU will transfer data to the MCU. The TTPTM system will be disinfected before use an alcohol-chlorhexidine solution. The Retrospective Phase, screening temperature data logs of patients who had sepsis or other fever related infection. Screening period shall be at least 72 hours prior to sepsis or infection detection. This part shall include 50 sepsis cases and 30 non-sepsis cases as a control. The Prospective Phase, measuring core temperature with the TTP and comparing it with existing technology such as rectal, esophageal or catheter or skin (by the case). The temperature data taken from each patient who will have a sepsis or other fever related infection will be analyzed to find any relation between the temperature pattern change Any medical care decision (such as microbiology cultures, additional testing, etc) will be made entirely according to existing reference standard of care. The TTP device will not influence in any way on ICU physician' decision. The TTP device purpose is only to record medical data for later evaluation and not to intertwine in medical care given to participants. This part shall include up to 600 patients who will be monitored and analyzed during their stay in the ICU in order to get at least 30 sepsis cases.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Patients in ICU

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
600 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
patients in ICU
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
TTP
Intervention Description
TTP™ allows to continuously measure body temperature using a new non-invasive method, and was cleared for marketing by US FDA (K150160) for as a temperature monitoring system intended to measure and monitor core body temperature of patients of all ages, by applying a sensor unit on the forehead.
Primary Outcome Measure Information:
Title
Continuously measure body temperature using TTP
Description
During the trial, temperature measurements will be conducted using the TTP™ and currently used thermometers which are in routine use, later to be regarded as reference methods To examine the effectiveness of the TTP™ as a measure for detection of temperature changes pattern and to correlate such changes with fever related to infections such as sepsis.
Time Frame
Estimated time frame of the trial is 18 months.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Study Participants - Patients hospitalized in ICU department. Inclusion Criteria: The Retrospective Phase Both genders (Male or Female). Aged 18 years and/or above. Patients were Admitted to our ICU for more than 3 days, and shall be at least 72 hours prior to sepsis or infection detection in the ICU The Prospective Phase Both genders (Male or Female). Aged 18 years and/or above. Patients expected to be admitted to our ICU for more than 3 days Exclusion Criteria: The patients will be excluded from the trial if one of the following occurs: The Retrospective Phase No exclusion criteria The Prospective Phase - The medical staff decides that the patien t should not participate. Unavailable measurement site in case of head injury in the head area. Unavailable measurement reading during admission to ICU
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Vered Nehemia, MD
Phone
02-5791921
Ext
846
Email
veredh@medisim.co.il
First Name & Middle Initial & Last Name or Official Title & Degree
Olga Yakov, MD
Phone
02-5791921
Ext
836
Email
olgay@medisim.co.il
Facility Information:
Facility Name
Hadassah Medical Center
City
Jerusalem
ZIP/Postal Code
POB 12000
Country
Israel
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Peter V Van Heerden, MD
Phone
02-6775976
Email
Vernon@hadassah.org.il
First Name & Middle Initial & Last Name & Degree
Magde Al Barade, MD
Phone
050-8946620
Email
Magdeaaa@hotmail.com

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Temple Touch Pro (TTP) Non-Invasive Core Temperature Monitoring as a Measure for Early Detection of Fever Related Infections, Including Sepsis.

We'll reach out to this number within 24 hrs